Mushrooms for Brain Diseases: Alzheimer's and Parkinson's

Mushrooms & Neuroinflammation

49 weeks

A 49-week double-blind placebo-controlled trial found that Erinacine A-enriched Lion's Mane significantly improved MMSE cognitive scores in mild Alzheimer's patients versus placebo. The first mushroom RCT showing significant cognitive improvement in Alzheimer's disease.

Li et al., Front Aging Neurosci, 2020

3 species

Lion's Mane, Ganoderma (reishi), and Cordyceps all have animal model or clinical data for neuroinflammatory conditions

7 targets

cordycepin from Cordyceps blocks 7 distinct neuroinflammatory molecular targets, from NF-κB to NLRP3 to HMGB1 (Govindula et al., 2021)

2 conditions

both Ganoderma and Lion's Mane showed neuroprotection in the MPTP dopaminergic neuron model used to study Parkinson's disease

Li et al., Front Aging Neurosci, 2020

View as image ↗

In 2020, a team of researchers in Taiwan published a 49-week double-blind placebo-controlled trial testing Erinacine A-enriched Lion's Mane mycelium in mild Alzheimer's patients. Patients taking Lion's Mane showed significantly improved MMSE scores (a standard cognitive assessment) compared to placebo by the trial's end.^[2]

This trial by Li and colleagues is the only randomized clinical trial of a mushroom compound for Alzheimer's disease that has shown significant cognitive improvement. Most mushroom neuroinflammation research remains in cell culture or animal models. Understanding the full scope of that evidence, what it shows, and what it doesn't yet prove, is what this guide covers.

Three mushroom species have accumulated the most neuroinflammatory data: Lion's Mane (Hericium erinaceus), Ganoderma lucidum (reishi), and Cordyceps. All three have been studied in models of Alzheimer's disease, Parkinson's disease, or general neuroinflammation. For the broader framework of how mushrooms fight inflammation through NF-κB and related pathways, see How Mushrooms Fight Inflammation: NF-κB, COX-2, and Beyond.

What Neuroinflammation Has to Do With Brain Disease

The brain is not immunologically silent. It has its own resident immune cells called microglia, which survey the brain for damage and respond to injury, infection, or abnormal protein accumulation. In healthy conditions, microglia maintain neural tissue and clear cellular debris. In neurodegenerative disease, they can shift into a persistently activated pro-inflammatory state that accelerates neuron loss.

In Alzheimer's disease, amyloid-beta plaques activate microglia into a pro-inflammatory state, releasing TNF-alpha, IL-1β, and IL-6 that damage surrounding neurons. In Parkinson's disease, microglia in the substantia nigra (the brain region that produces dopamine) become overactivated in response to dying dopaminergic neurons, creating an inflammatory feedback loop that accelerates dopaminergic degeneration.

Neuroinflammation is now considered a central mechanism in both diseases, not merely a side effect. This is why researchers have investigated whether compounds that regulate microglial activation, including those from medicinal mushrooms, could slow disease progression.

For a mechanistic deep dive into how different mushroom species regulate microglial activation and shift the M1/M2 polarization balance, see How Mushrooms Regulate Microglial Activation.

Alzheimer's Disease: From Mouse Model to Clinical Trial

The Lion's Mane research on Alzheimer's follows an unusually complete evidence chain for a mushroom study: cell culture, then transgenic mice, then a clinical trial.

Tsai-Teng and colleagues in 2016 fed Erinacine A-enriched Lion's Mane mycelium to APPswe/PS1dE9 mice, a standard genetic model of Alzheimer's disease that develops amyloid-beta plaques and cognitive decline. After 30 days of oral administration, the treated mice showed reduced amyloid-beta plaque burden in the brain, lower neuroinflammatory markers, and improved behavioral outcomes compared to untreated controls.^[1] This study established Erinacine A, a diterpenoid compound from Lion's Mane mycelium, as the likely bioactive driver of the neuroinflammatory effects.

The clinical trial from Li and colleagues in 2020 then tested a product standardized to 5 mg/g erinacine A content, giving patients 3 capsules per day for 49 weeks in a double-blind, placebo-controlled design.^[2] Patients taking Lion's Mane showed significantly improved MMSE scores compared to placebo. MMSE (Mini-Mental State Examination) is the standard clinical instrument for measuring cognitive function in Alzheimer's research; a significant improvement is the outcome that pharmaceutical trials aim for.

Important context for interpreting this result: this was a pilot study, and Li and colleagues explicitly describe it as such. The sample size was small. The 49-week timeframe is long by clinical trial standards but short relative to Alzheimer's disease progression. Replication in larger trials is needed before clinical conclusions can be drawn. What this trial does establish is proof of concept: the compound chain from Erinacine A in Lion's Mane mycelium to measurable cognitive improvement in human Alzheimer's patients has been demonstrated once, in a controlled design, with statistical significance.

Key Study

Li et al. (2020) · Frontiers in Aging Neuroscience

Population

Patients with mild Alzheimer's disease

Intervention

Three 350 mg H. erinaceus mycelia capsules per day (5 mg/g erinacine A active ingredient) for 49 weeks

Comparator

Identical-appearance placebo, randomized, double-blind

Finding

Significant improvement in Mini-Mental State Examination (MMSE) score in the treatment group versus placebo, along with better contrast sensitivity; the placebo group showed a significant decline on the Cognitive Abilities Screening Instrument.

preliminary Authors describe it explicitly as a pilot study. Small sample; a proof-of-concept signal, not clinical proof. Needs replication in larger, more diverse trials.

Li et al., Frontiers in Aging Neuroscience, 2020

Evidence Ladder

1. Cell / mechanismcompleted

   Erinacine A identified as the bioactive driver of Lion's Mane's neuroinflammatory effects

2. Animal modelcompleted

   Tsai-Teng 2016: reduced amyloid-beta plaque and microglial activation in APPswe/PS1dE9 mice

3. Pilot / small RCTcurrent

   Li 2020: 49-week double-blind pilot, significant MMSE improvement vs placebo

4. Large confirmatory RCTmissing

   Not yet done — the single most important missing step

5. Meta-analysismissing

   Not possible until multiple trials exist

Among all mushroom-for-brain-disease research, only Lion's Mane for Alzheimer's has climbed from cell and animal work to an actual human trial. That trial is a single small pilot — encouraging, but two full rungs short of the large confirmatory RCT that clinical recommendations would require.

Tsai-Teng et al. 2016; Li et al. 2020

For the specific compounds in Lion's Mane responsible for these effects, including the distinction between hericenones (from the fruiting body) and erinacines (from the mycelium), see Hericenones and Erinacines: Lion's Mane's Brain-Boosting Compounds.

Parkinson's Disease: Two Species, One Animal Model

Parkinson's disease research typically uses the MPTP model: a chemical called MPTP selectively destroys dopaminergic neurons in the substantia nigra, replicating the pattern of neuronal loss seen in human Parkinson's disease. It is the most widely used animal model for Parkinson's research.

Ganoderma lucidum has been studied in this model twice, by the same research group, at different mechanistic levels.

Ren and colleagues in 2019 showed that Ganoderma lucidum extract protected dopaminergic neurons in MPTP-treated mice by regulating mitochondrial function, reducing oxidative stress, and modulating the autophagy and apoptosis pathways.^[5] The neurons survived at higher rates in the treated group, and the mechanisms involved were neuroprotective at the cell level.

Ren and colleagues in 2022 returned to the MPTP model to specifically examine neuroinflammation in the nigrostriatal region, the brain pathway from the substantia nigra to the striatum that degenerates in Parkinson's.^[4] Ganoderma extract repressed MPTP-induced microglia activation in this region, modulated the abnormal cytokine expression, and worked through inhibition of the iNOS and NLRP3 pathways and regulation of microglial autophagy. The 2022 paper added the neuroinflammation angle to the 2019 paper's neuroprotection data, showing that the two are connected: Ganoderma appears to protect dopaminergic neurons partly by dampening the microglial inflammatory response that accelerates their death.

Lion's Mane through Erinacine A also shows Parkinson's-relevant effects. Lee and colleagues in 2020 demonstrated that Erinacine A, given after MPTP administration (a more clinically realistic test than pre-treatment), reduced dopaminergic neuron loss and attenuated neuroinflammation in the MPTP mouse model.^[3] The post-treatment design is significant because most patients would be diagnosed and treated after neuronal loss has already begun, not before. The fact that Erinacine A showed effects in a post-treatment paradigm is a more translatable finding than pre-treatment efficacy.

Two different species (Ganoderma and Lion's Mane), two different compound classes (polysaccharides and diterpenoids), both reaching dopaminergic neuron protection in the same validated disease model through overlapping but distinct pathways: this pattern of convergent evidence is more convincing than any single study.

For a deeper look at how Ganoderma and Lion's Mane work together at the microglial level, see Mushrooms and Brain Inflammation: Microglial Modulation Across Species.

Cordyceps: The Most Mechanistically Detailed Species for Neuroinflammation

Cordyceps has less clinical or animal-model data for specific neurological conditions compared to Lion's Mane and Ganoderma. What it does have is the most detailed mechanistic mapping of any mushroom species for neuroinflammation: cordycepin, its primary bioactive compound, has been shown to inhibit neuroinflammation through at least 7 distinct molecular targets.

Govindula and colleagues in 2021 mapped cordycepin's anti-neuroinflammatory mechanisms in a comprehensive review, identifying inhibition of: adenosine A2 receptor, NF-κB, NLRP3 inflammasome, IL-1β, iNOS, COX-2, and HMGB1.^[6]

Each of these targets represents a different point in the neuroinflammatory cascade. Adenosine A2 receptor modulation affects microglial activation state upstream. NF-κB inhibition blocks transcription of multiple pro-inflammatory genes at once. NLRP3 inflammasome inhibition prevents the IL-1β processing that amplifies neuroinflammation. HMGB1 suppression reduces late-stage alarm signaling that sustains chronic neuroinflammation. Inhibiting all seven simultaneously, rather than just blocking one pathway, suggests broad anti-neuroinflammatory coverage.

The limitation: this mechanistic profile comes primarily from cell culture data, with some animal evidence. There are no clinical trials of cordycepin specifically for neuroinflammatory conditions comparable to the Li 2020 Lion's Mane Alzheimer's study.

The Evidence Table: Conditions, Species, and What the Data Shows

The table reveals a clear asymmetry: Alzheimer's has the best evidence (both animal and human clinical), Parkinson's has convergent animal evidence from two species, and general neuroinflammation is the most mechanistically detailed but clinically untested territory.

Three Species, Three Evidence Altitudes

How High Up the Ladder Each Species Has Actually Climbed

The three most-studied mushrooms for neuroinflammatory conditions sit at very different points on the evidence ladder. Only Lion’s Mane has reached a human trial — a single 49-week pilot RCT. Ganoderma stops at convergent animal data; Cordyceps is the most mechanistically detailed but has never been tested for a specific neurological condition. Reading the altitude, not the breadth, is what keeps expectations honest.

Lion's Mane (Hericium erinaceus)

Alzheimer's + Parkinson's

Cell -> animal -> human pilot

Compound

Erinacine A (diterpenoid)

Reached

Pilot RCT

Evidence

Full chain: amyloid + microglia reduction in APPswe/PS1dE9 mice [1] -> 49-week double-blind pilot RCT with significant MMSE improvement [2]; plus post-treatment dopaminergic protection in the MPTP Parkinson's model [3]

Refs

[1] [2] [3]

Ganoderma (reishi) (Ganoderma lucidum)

Parkinson's disease

Two in-vivo studies

Compound

Whole extract (polysaccharide-rich)

Reached

Animal model x2

Evidence

Convergent MPTP evidence from one group: dopaminergic neuroprotection via mitochondrial/oxidative-stress regulation [5], then microglial suppression in the nigrostriatal region via iNOS/NLRP3 [4]

Refs

[4] [5]

Cordyceps (Cordyceps spp.)

General neuroinflammation

Mechanistic review, cell-led

Compound

Cordycepin (adenosine analogue)

Reached

Mechanism / cell

Evidence

Most detailed mechanistic map of any species — cordycepin documented against 7 targets (adenosine A2, NF-kB, NLRP3, IL-1b, iNOS, COX-2, HMGB1) [6] — but no condition-specific animal or human trial

Refs

[6]

The whole field rests on a single human trial: the Li 2020 pilot RCT of Erinacine A-enriched Lion’s Mane [2]. Everything else — the Ganoderma Parkinson’s work [4][5] and the Cordyceps mechanism map [6] — is animal or cell-culture data. Convergence across species and models is encouraging, but no mushroom has climbed to a large confirmatory RCT or meta-analysis for any neuroinflammatory condition.

Evidence synthesis; cells from refs [1]–[6] (see references)

The same asymmetry, read as altitude, is what matters most for setting expectations: it is not that one species "works" and the others don't, but that only one species has been carried far enough up the evidence ladder to have any human data at all.

The Translation Gap: What Animal Models Don't Tell Us

The MPTP model is validated and widely used, but it is not Parkinson's disease. MPTP causes acute, chemically induced dopaminergic neuron death over days, while Parkinson's disease involves a decades-long neurodegenerative process. A compound that protects against MPTP injury may or may not affect the slow progressive neurodegeneration of actual Parkinson's disease in humans.

Similarly, the APPswe/PS1dE9 transgenic mouse used in the Tsai-Teng 2016 study develops amyloid pathology because of specific genetic mutations; human sporadic Alzheimer's is genetically and environmentally more complex. Animal model results have historically over-predicted success in Alzheimer's clinical trials.

The Li 2020 clinical trial is therefore significant not just for its finding but for its existence: it represents the step across the translational gap. The result was significant, but it was a pilot study and needs replication in larger, more diverse populations before clinical recommendations can follow.

No mushroom is approved or established as a treatment for any neuroinflammatory condition. The research reviewed here establishes biological plausibility and, in the case of Li 2020, a proof-of-concept clinical signal. The distance between that and clinical practice is large.

Safety & Scope

Moderate

This Research Is Not a Treatment Recommendation

Concern

No mushroom or mushroom compound is approved or clinically established as a treatment for Alzheimer's, Parkinson's, or any neuroinflammatory condition. Apart from the single Li 2020 pilot RCT, the evidence here is preclinical (cell and animal models), and animal results have historically over-predicted success in human neurodegeneration trials.

What the research says

Treat these findings as biological plausibility and early signals, not as a basis for self-treatment and not as a reason to delay, replace, or stop prescribed care.

Particularly relevant for: Anyone with, or caring for someone with, a diagnosed neurodegenerative condition

What to do

Discuss any supplement use with the treating physician or neurologist first, especially alongside existing medications, and do not substitute mushrooms for standard treatment.

Synthesis of the reviewed evidence; not medical advice.

For a broader look at how mushroom compounds modulate cytokines throughout the body, including anti-inflammatory mechanisms beyond the brain, see How Mushrooms Modulate Inflammatory Cytokines and Mushrooms and Brain Inflammation: Neuroprotective Effects.

The Bottom Line

Lion's Mane holds the strongest clinical evidence for a neuroinflammatory condition: a 49-week RCT showing Erinacine A-enriched mycelium significantly improved MMSE scores in mild Alzheimer's patients. Ganoderma lucidum has convergent animal data in the Parkinson's MPTP model, showing both dopaminergic neuroprotection and microglial suppression in the nigrostriatal region through two independent studies. Cordyceps contributes the most detailed mechanistic map, with cordycepin documented to target seven distinct neuroinflammatory molecular pathways. Almost all of this evidence is preclinical; the Li 2020 RCT is the notable clinical exception and needs replication.

Frequently Asked Questions

What mushrooms help with Alzheimer's disease?

Lion's Mane (Hericium erinaceus) has the strongest evidence. A 49-week double-blind RCT by Li and colleagues found that Erinacine A-enriched Lion's Mane mycelium significantly improved MMSE cognitive scores in mild Alzheimer's patients versus placebo. Animal data from Tsai-Teng and colleagues also showed Erinacine A-enriched Lion's Mane reduced amyloid-beta plaque burden in Alzheimer's transgenic mice. This is a pilot study and needs replication, but it represents the only mushroom clinical trial to show significant Alzheimer's cognitive improvement to date.

Are mushrooms good for Parkinson's disease?

In animal models, yes: both Ganoderma lucidum and Lion's Mane have protected dopaminergic neurons in the MPTP model of Parkinson's disease. Ren and colleagues showed Ganoderma suppressed microglia activation in the nigrostriatal region and protected dopaminergic neurons across two separate MPTP studies (2019, 2022). Lee and colleagues showed Erinacine A from Lion's Mane protected dopaminergic neurons in a post-treatment MPTP paradigm. No clinical trials of mushrooms for Parkinson's disease in humans have been published.

Can mushrooms reduce neuroinflammation in MS?

There are no clinical trials or direct animal models of multiple sclerosis (MS) for mushroom compounds in the studies reviewed here. Cordycepin's multi-target anti-neuroinflammatory mechanism (Govindula et al., 2021) is theoretically relevant to the neuroinflammation that drives MS lesions, and that same review notes cordycepin's promotion of remyelination, the myelin-repair process that fails in MS. This remains an open research question, with no MS-specific trials or animal models among the studies reviewed here; no evidence currently supports mushrooms as a treatment for MS.

Which mushrooms have the most evidence for brain diseases?

Lion's Mane has the most evidence overall, including the only clinical RCT showing significant cognitive improvement in Alzheimer's disease (Li et al., 2020) and animal data in both Alzheimer's and Parkinson's models. Ganoderma lucidum has the strongest animal evidence for Parkinson's disease, with two independent studies from the same model. Cordyceps has the most mechanistically detailed anti-neuroinflammatory profile through cordycepin's seven molecular targets, but lacks the condition-specific animal or clinical data of the other two species.

Is Lion's Mane proven to help Alzheimer's disease?

A 49-week double-blind placebo-controlled pilot study showed significant MMSE cognitive improvement with Erinacine A-enriched Lion's Mane vs. placebo in mild Alzheimer's patients. This is a proof-of-concept finding, not clinical proof. Li and colleagues explicitly describe it as a pilot study; the sample size was small and the result needs replication in larger trials. It is currently the strongest evidence that a mushroom compound can affect Alzheimer's cognitive outcomes, but it is not sufficient to establish Lion's Mane as a proven Alzheimer's treatment.

Sources & References

1. 1RTHM-00452·Tsai-Teng, Tzeng et al. (2016). “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice..” Journal of biomedical science.Study breakdown →PubMed →↩
2. 2RTHM-00631·Li, I-Chen et al. (2020). “Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
3. 3RTHM-01229·Lee, Kam-Fai et al. (2020). “Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson's Disease..” Antioxidants (Basel.Study breakdown →PubMed →↩
4. 4RTHM-01609·Ren, Zhili et al. (2022). “Ganoderma lucidum Modulates Inflammatory Responses following 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice..” Nutrients.Study breakdown →PubMed →↩
5. 5RTHM-01118·Ren, Zhi-Li et al. (2019). “Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis..” Acta pharmacologica Sinica.Study breakdown →PubMed →↩
6. 6RTHM-01359·Govindula, Anusha et al. (2021). “Molecular mechanisms of cordycepin emphasizing its potential against neuroinflammation: An update..” European journal of pharmacology.Study breakdown →PubMed →↩